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Abstract  
Background: Muscle atrophy is the shrinkage of muscle fibers that are largely maintained by a 
balance of protein synthesis and degradation.  Imbalances in protein synthesis and degradation 
are observed in different muscle atrophy disorders such as cancer cachexia and disuse.  These 
forms of muscle atrophy produce distinct wasting pathologies that are influenced by biological 
sex.  Activin receptor type-2B (ACVR2B) and Growth factor receptor-bound protein 10 
(GRB10) have been identified as genes that potentially regulate muscle mass while also 
displaying sexually dimorphic differences.  Purpose: To examine the influence of ACVR2B and 
GRB10 throughout the development of cancer cachexia and disuse-induced atrophy in male and 
female mice.  Methods: Lewis Lung Carcinoma (LLC) was injected into the hind flank of male 
and female C57BL6/J mice at 8 weeks of age.  Tumors were allowed to develop for 1, 2, 3, or 4 
weeks and were compared to a PBS control.  Disuse-induced male and female C57BL6/J mice 
were hindlimb unloaded for 24 hours, 48 hours, 72 hours, and 168 hours and were compared to 
cage control mice.  RT-qPCR was used to measure mRNA content of ACVR2B and GRB10 of 
the gastrocnemius muscle.  Results:  LLC female mice had ~35% lower ACVR2B mRNA 
content compared to PBS control with a ~40% and ~30% lower content at LT and HT compared 
to 2-week LLC animals (p<0.05).  LLC male ACVR2B mRNA contents were significantly lower 
by ~48%, ~56%, and ~36% at one, two, and four weeks, respectively, of tumor-bearing 
compared to PBS control mice (p=0.0006). No significant differences were observed in GRB10 
mRNA content in LLC female mice across all cohorts.  GRB10 mRNA content in LLC males 
was significantly lower by ~41% after one week of tumor implantation compared to LLC PBS 
control mice (p=0.0094).    ACVR2B mRNA content in HU female mice was not significantly 
different across all cohorts (p=0.192).  HU males displayed a ~two-fold lower ACVR2B mRNA 
 
content after 3 days compared to cage control mice (p=0.0233) and 7 days of unloading 
(p=0.015).  GRB10 mRNA content in HU males was significantly lower at 2 and 3 days with a 
~51% lower content compared to control mice with also a ~two-fold decrease compared to 7 
days of hindlimb unloading.  Conclusions:  ACVR2B and GRB10 content displayed differential 
responses during cancer cachexia and disuse-induced muscle atrophy that varied by sex.  Data 
suggests that ACVR2B and GRB10 play a greater role in males during muscle atrophy than 
compared to females.  Future experiments incorporating additional muscle groups are warranted 
to better understand the pathways of ACVR2B and GRB10 and their influence between sexes 
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I. Literature Review 
Muscle Wasting Overview 
Muscle atrophy is defined as the shrinkage of muscle fibers due to the loss of contractile 
proteins and organelles.1  Skeletal muscle mass is largely maintained by a balance between 
protein synthesis and degradation contributing to overall muscle mass.2  When an imbalance of 
protein synthesis and degradation occur, muscle atrophy can be observed as seen in disorders 
such as cancer and disuse.3, 4  Cancer cachexia and muscle disuse produce distinct wasting 
pathologies and understanding the mechanisms and pathways associated with each can aid in the 
development of preventative and possibly, curative treatments.2  Muscle atrophy is further 
associated with muscle weakness and fatigue contributing to a reduced quality of life.5  
Therefore, it is clinically important to further investigate the mechanisms in different pathologies 
that contribute to muscle atrophy and the preservation of muscle mass.   
Looking specifically at cancer cachexia and disuse-induced muscle wasting, I will 
investigate the different patterns of wasting between male and female mice with a specific focus 
of the genes associated with muscle growth such as Activin receptor type-2B (ACVR2B) and 
Growth factor receptor-bound protein 10 (GRB10).  Because recent evidence demonstrates sex-
related differences in response to different types of muscle atrophies such as cancer cachexia and 
disuse-induced,6 it is of great benefit to further investigate these differences as increased 
understanding can advance knowledge and therapeutic strategies in muscle atrophy.  These genes 
have previously been shown to be significant regulators of muscle mass with prevalent 
dimorphic expression but have not been systematically investigated to determine their roles in 
muscle homeostasis during disuse and cancer cachexia-induced muscle atrophy.7  This observed 
sex-related difference in expression will be further built upon by examining how cancer cachexia 
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and disuse-induced muscle atrophy influences the expression of ACVR2B and GRB10 in male 
and female mice.   
 
Cancer Cachexia 
Cancer cachexia is defined as the decrease of skeletal muscle and adipose tissue masses, 
with the development of cancer, that cannot be reversed by nutritional support alone.8  Cancer 
cachexia contributes to the death of an estimated 2 million people worldwide each year.5, 9  It is 
estimated that 1.8 million Americans will be diagnosed with cancer in the year 2020 while an 
estimate 606,520 will die from the disease.10  Cachexia is estimated to be the primary cause of 
death for approximately 30% of cancer patients.11  In addition, cancer cachexia is often 
associated with pancreatic, esophageal, lung, liver, stomach, and bowel cancer.12   
There are multiple mechanisms involved in the development of cancer cachexia, many 
including physiologic responses driven by inflammation and pro-inflammatory cytokine activity 
which has been associated with muscle wasting.3  A favored atrophy of Type II muscle fibers is 
observed with cancer cachexia displaying a fast-to-slow fiber type shift.13  To date, there are no 
reversible treatments of cancer cachexia and therapy remains focused on supplying nutritional 
support while researchers investigate approaches that can target and reduce overactivation of cell 
injury and inflammation.12 
 
Disuse-induced Atrophy 
 Prolonged muscle disuse is an inducible form of muscle wasting.  This type of atrophy 
can be observed with prolonged bed rest, casting, immobilization, and limb unloading.6, 14  
Disuse can lead to a reduction in muscle mass, fiber size, strength, and function with the extent 
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varying on the length of disuse and the specific muscle.14  Disuse atrophy is fiber type 
dependent, however, in contrast with cancer cachexia, disuse presents with a greater 
susceptibility of oxidative, Type I muscle fibers.6  A greater percentage loss of fiber cross-
sectional area is observed in Type I muscle fibers than compared to Type II muscle fibers 
affecting specific muscles differently based on fiber type composition.4  Studies have shown that 
skeletal muscle mass and strength can decrease 6-24% following various types of disuse.15  
These values are dependent on the muscle type and extent of unloading.4  Unlike cancer 
cachexia, disuse atrophy does not display an inflammatory action.6   
There are many proposed pathways contributing to muscle atrophy observed with disuse.  
Molecular signal changes in pathways such as the Protein kinase B (also known as AKT)-
Mechanistic target of rapamycin (mTOR) pathway and Myostatin pathway display skeletal 
muscle protein adaptations that occur through disuse.  Activation of AKT via phosphorylation 
activates mTOR kinase leading to the activation of Ribosomal protein S6 kinase beta-1 
(p70S6K), a translation initiation factor involved in regulating protein synthesis, remaining as an 
essential part of muscle protein synthesis.15-17  AKT-mTOR pathway is not activated in disuse 
conditions leading to muscle atrophy.15  While there is a decrease in basal protein synthesis, 
there is limited evidence of protein degradation observed in humans.4  Treatments to combat 
disuse muscle atrophy remain minimal due to a lack of understanding of the molecular and 
cellular mechanisms responsible for atrophy.  Therefore, further investigation on regulation of 






Muscle Sex Differences 
Characteristics of muscle atrophy varies depending on the cause of wasting as well as 
biological sex.  Sex hormones play a significant role in muscle homeostasis ranging from 
anabolism, regeneration, and inflammation, sometimes acting as protective factors.18  Males 
largely express testosterone that actively promotes muscular regeneration and protein synthesis 
through androgen receptor signaling.19  Females, having lower levels of testosterone, express 
estrogen which has a protective effect by mitigating inflammation in skeletal muscle.18  Other 
studies have demonstrated a potential protective effect from female sex hormones in disuse 
atrophy.20  Because of these sex differences and varying hormonal profiles, it is important to 
investigate the influence sex can have on different atrophy conditions.  Cancer cachexia and 
disuse atrophy have markedly different characteristics associated with each which is influenced 
by biological sex.21  While there are various sex-differences that influence muscle phenotype, 
function, and regulation,6 little investigation has focused on the biological sex differences and 
mechanisms during wasting and warrants further investigation.21   
Looking at the muscle composition between sexes, women have a larger relative 
composition of Type I muscle fibers and depend more on oxidative metabolism compared to 
males.6  Conversely, males have a larger ratio of Type II glycolytic muscle fibers and a greater 
muscle mass.6  This difference in muscle fiber type composition influences the ways males and 
females atrophy during disuse and cancer cachexia due to the two types of wasting differential 
responses.  
Cancer cachexia favors the atrophy of Type II glycolytic muscle fibers and displays a 
fast-to-slow muscle fiber type switch.13  Males experiencing cancer cachexia have been shown to 
lose a greater percent of body weight, rapidly losing muscle and fat, compared to females whose 
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fat mass declines initially but lose muscle more gradually.18  Overall, females appear to be more 
protected from the inflammation induced muscle wasting which occurs during cancer cachexia 
when compared to males who have greater muscle losses.6   
Disuse-induced favors atrophy of oxidative myofibers.21  Muscles predominantly 
composed of slow twitch fibers, such as postural muscles, are highly susceptible to disuse and 
can display fiber shifts towards fast glycolytic phenotypes.15  Because muscle composition varies 
between the sexes, it is important to consider sex when investigating disuse atrophy.  As 
previously stated, females have a relatively larger composition of Type I oxidative muscle 
fibers.6  Research has shown that atrophying skeletal muscle has an increase in oxidative stress 
and that estradiol can act as both a membrane stabilizer and antioxidant.20  Few studies have 
specifically focused on the potential influence sex differences can have on disuse atrophy, but 
research has shown that women lose muscle faster compared to males.6  Women have also been 
shown to display a greater loss of strength in isometric and concentric contractions compared to 
males after short-term immobilization.20  Despite a previous study showing men and women 
having similar decreases in cross-sectional area after disuse-induced, men retained a greater 
degree of specific strength compared to females.20   
While sex differences have been observed through disuse-induced atrophy, it is not clear 
whether these differences can be attributed to the favorable atrophy of Type I oxidative muscle 
fibers that are more abundant in females, or if there are other differences in muscle physiology 
between sexes.6  Understanding the wasting characteristics of cancer cachexia and disuse-
induced and the differences that are present between sexes create the foundation for 





ACVR2B is an activin and part of the TGF Beta family.22  It is a protein coding gene and 
encodes a myostatin receptor involved in growth factor pathways known to regulate muscle 
mass.7  Activin type II receptors are capable of binding myostatin, a negative regulator of muscle 
growth that blocks myogenic development, and other TGF Beta family members.23  TGF Beta 
family receptors and ligands control progenitor activation and muscle growth formation.24  
Previous research has shown increased muscle mass and promoted skeletal muscle growth in 
mice following the administration of soluble ACVR2B.25  The soluble form of ACVR2B leads to 
the suppression of myostatin.24  Muscle mass increases of up to 60% have been observed in wild-
type mice following soluble ACVR2B administration.23  Further research and better 
understanding of ACVR2B may be clinically beneficial in the prevention of muscle atrophy and 
can aid in treatments of degenerative myopathies, like cancer cachexia.  Pathways involving 
ACVR2B are yet to be fully understood whether they act primarily upon myofibers or target 
additional cell types.24 
The binding of myostatin is proposed to signal through two activin receptors, ACVR2A 
and ACVR2B.26  Activin type 1 receptors are activated and phosphorylated through the binding 
of myostatin to ACVR2B which leads to intracellular signaling of receptor-regulated proteins, 
Smad2 and Smad3.25  Smad2, Smad3, and Smad4 are required for myostatin-induced 
transcription.27  Administration of soluble ACVR2B has shown to inhibit muscle and adipose 
wasting in cachexia by targeting myostatin-family ligands.28  
Inhibition of myostatin binding has previously been shown to be a therapeutic approach 
to preserving muscle mass in cancer cachexia.28  A proposed mechanism of muscle wasting 
observed in cachexia is increased signaling of activin receptor ligands.29  Blocking of these 
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ligands and their receptors can prevent muscle atrophy as well as increase of muscle mass.  
Soluble ACVR2B produced an increase of muscle mass by 23-40% in a study performed by 
Benny Klimek et al.28  While this study effectively showed that ACVR2B promotes muscle 
preservation in cancer cachexia, the protective effect may be due to other myostatin targets and 
the underlying mechanisms are yet to be fully uncovered.  Other studies have shown that 
blocking of activin receptor ligands can improve survival of cancer with improved limb and 
respiratory muscle mass.29  In addition, Huot et al30 demonstrated the complete preservation of 
cardiac and muscle function as well as preservation of adipose tissue, bone, and skeletal muscle 
in tumor hosts receiving ACVR2B/Fc.  While there is previous research focused on ACVR2B’s 
protective effect of muscle mass throughout cancer cachexia, research is not as prevalent on its 
impact in disuse-induced and potential differences in expression between sexes.  Studies focused 
on cancer cachexia have briefly mentioned ACVR2B’s protective effect on muscle mass in other 
myopathies often including disuse.  
When examining the expression of ACVR2B between sexes, to my knowledge, one study 
has observed to be expressed at 1.6-fold greater in women compared to men using quantitative 
RT-PCR.7  Difference in the expression of ACVR2B between sexes is scarce but few 
associations have been observed in regard to cancer treatments incorporating both sexes.  A 
study on liver cancer investigating levels of ACVR2B-AS1 showing that liver cancer specimens 
contained significantly elevated levels of ACVR2B-AS1 and that women with higher levels had 
shorter relapse-free survival compared to those with lower ACVR2B-AS1 levels.31  This study 
further showed that ACVR2B could be a beneficial therapeutic target in cancer treatment and 
prognosis.  Further investigation is warranted to understand sexual dimorphic expression of 
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ACVR2B in cancer cachexia and disuse for the preservation of muscle mass and advanced 
treatment opportunities.  
 
GRB10  
 Growth factor receptor-bound protein 10 is an adapter protein that interacts with the 
insulin receptor by binding to and suppressing signaling.32  It is involved with many tyrosine-
phosphorylated growth factor receptors and is highly expressed in muscle, pancreas, and adipose 
tissues that involve glucose metabolism and insulin action.33  Variations in GRB10 expression 
alter insulin receptor protein levels.32  GRB10 negatively regulates insulin signaling with the 
inhibition of insulin receptor kinase activity by facilitating degradation of the receptor.  By 
controlling the receptor, activation of growth factors can be regulated.34  
 GRB10 has been shown to play an important role in the regulation of muscle size and 
muscle metabolism.33  Studies involving mice with the loss of GRB10 resulted in increased 
signaling of the insulin receptor in muscle tissue and increased glucose uptake.35  GRB10 knock 
out mice have also shown hyperplasia of muscle cells.33  A study performed by Smith et al35 
compared muscle and adipose mass from birth to one-year of male and female wild-type mice 
and disrupted GRB10 mice.  This study showed that male and female GRB10 mice were 
approximately 13% heavier with reduced adiposity at six months compared to wild-type 
littermates.35  
In addition to insulin receptor signaling, GRB10 is also a substrate for mTOR complex 
1.36  Edick et al.36 characterized the function of GRB10 and its regulation of mTORC1 in human 
muscle.  This study proposed that mTORC1 controls phosphatidylinositide 3-kinase (PI3K) 
signaling by GRB10 through alteration of insulin receptor abundance.  The PI3K/Akt pathway 
 
9 
plays great significance for metabolic actions of insulin including glucose uptake and glycogen 
synthesis in skeletal muscle.  GRB10 silenced myotube showed increased insulin responsiveness 
with enhanced insulin-induced PI3K/Akt signaling with a higher abundance of the insulin 
receptor.36  Emerging research into cancer cachexia has focused on the influence and 
contribution of mTOR and mTOR inhibitors.37  GRB10 stabilizes mTORC1 which participates 
in cell proliferation and survival.  With GRB10’s role in regulating mTORC1 and its negative 
feedback on PI3K/Akt signaling not yet being fully established, research into the expression of 
GRB10 in cancer can contribute further insight. 
Differences in insulin receptor gene expression has been observed to be higher in women 
by a 3-fold increase.7  Because GRB10 expression can restrain IGF-1 signaling, Welle et al7 
proposes that a greater GRB10 expression may contribute to sex differences in muscularity.  This 
hypothesis is supported from Smith et al35 where GRB10 knockout mice exhibited increased 
muscularity.  Similar to ACVR2B, literature of sexual dimorphic expression of GRB10 is limited 
and warrants further investigation.  In addition, the influence GRB10 has on skeletal muscle 
makes it an important contender towards investigating changes in expression that may occur 
during muscle atrophy in cancer cachexia and disuse.  
 
Purpose 
 Considering the potential interplay with muscle growth mechanism and the limited 
knowledge regarding the roles of ACVR2B and GRB10 during muscle atrophies between males 
and females, the purpose of this work is to better understand biological sex differences in 
ACVR2B and GRB10 expression during cancer cachexia and disuse-induced muscle atrophy.  
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This study will aid in improved treatment and preventative therapies to counteract the 
progression of muscle atrophy.  
 
Objectives for Data Analysis 
• Describe muscle atrophy characteristics observed between disuse-induced and cancer 
cachexia 
• Describe difference of muscle wasting in males versus females during disuse-induced and 
cancer cachexia samples 
• Assess differences in expression of ACVR2B and GRB10 during disuse-induced and 
cancer cachexia samples 
• Determine differences in expression of ACVR2B and GRB10 in males and females 
• Further experiments may be pursued as dictated by data outcomes 
 
II. Methods 
Animal experiments for this proposal were previously approved by the University of 
Arkansas Institutional Animal Care and Use Committee and performed by Dr. Greene’s 
laboratory group.  My work does not involve direct use of research animals but is limited to 
analysis of muscle tissue samples previously collected.  This thesis involves analysis of collected 
tissue samples from two different models of muscle atrophy; hindlimb suspension for induced-






Animals and Intervention 
The mice utilized for this study were a cohort of male and female C57BL/6J mice 
purchased from Jackson Laboratories (Bar Harbor, ME, USA).  All animal experiments were 
performed at the University of Arkansas in Fayetteville, Arkansas and have been approved by 
the Institutional Animal Care and Use Committees of the University of Arkansas.  These animals 
were housed to meet the requirements for hindlimb suspension as well as being placed in a 
temperature-controlled environment maintained on a 12:12 h light-dark cycle.  The mice 
received ad libitum access to normal rodent chow and water. The mice utilized for induced 
cancer cachexia received LLC implantation at 8 weeks in the hind flank.  I did not personal 
perform animal work in this thesis; all animal work was previously performed and I am solely 
working with tissue analyses.  
 
Hindlimb Suspension 
Induced muscle atrophy of the skeletal muscle was produced by hindlimb suspension as 
previously described.38-40  Prior to hindlimb suspension, mice were acclimatized to handling by 
researchers for one week before being subjected to seven days of suspension.  Animals’ tails 
were first sterilized using ethanol wipes followed by iodine swabsticks.  After which, tails were 
coated with benzoin to increase adhesiveness of the tail.  Appropriate size of athletic tape was 
then wrapped around the base of the animals’ tail and a small stainless-steel hook was then 
connected to the athletic tape and adjusted to allow normal blood circulation.  Fishing string was 
then utilized to connect between the hook and a custom designed pulley system to allow for 
unloading of the hindlimb legs, allowing only forelimbs to have contact with the cage floor with 
a suspension angle of 30-45 degrees.  The unloading system involved a single rod that reaches 
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across the cage allowing access to all areas but limiting contact with cage walls to prevent 
potential hindlimb loading.  The cage floor was fitted with grid wire with only a small amount of 
bedding to prevent hindlimb loading from mounded up bedding.  Animals were monitored daily 
to ensure unloading of hindlimbs as well as signs of tail necrosis or distress.  With the mice 
being suspended for seven days to induce disuse atrophy, the bedding materials were not 
replaced through the course of the experiment.  Disuse was allowed to develop over a time 
course to create the following experimental groups: cage control, 24 hours, 48 hours, 72 hours, 
and 168 hours of disuse.  The length of disuse has been shown to induce disuse atrophy in both 
male and female animal models.41-44  
 
Lewis Lung Carcinoma Cell Culture and Implantation 
 Lewis lung carcinoma cells (ATCC CRL-164) were used for this project.  LLC cell 
culture and harvest were prepared as previously described by Brown et al.45  Briefly, these cells 
were plated in 250 mL culture flasks in DMEM with 10% fetal bovine serum supplemented with 
1% penicillin and streptomycin.  Upon confluency, cells were trypsinized, suspended, counted, 
and diluted in PBS for implantation.  At 8 weeks of age, mice were implanted with LLC (1 x 106 
cells in 100 uL of PBS) subcutaneously in the hind flank where the tumor was allowed to 
develop for 1-4 weeks in separate cohorts of animal.  A control group was given an equal volume 
of PBS at 8 weeks of age while also aged-matched with 4 weeks of tumor bearing mice.  At the 
time of harvest, mice were 12 weeks in age. This method has been widely used to induce cancer 




Tissue Collection and Sample Preparation 
After the suspension and cancer-induced cachectic periods, animals were anesthetized 
under isoflurane.  Tissue samples of the plantaris, gastrocnemius, soleus, extensor digitorum 
longus; EDL, tibialis anterior; TA, heart, tumor, lungs, spleen, epididymal fat, and plasma were 
collected, and mice were humanely euthanized while under anesthesia.  Tissue sample weights 
were recorded and snap-frozen in liquid nitrogen.  Tissues were stored at -80°C for further 
analyzation.  For the purpose of this thesis, the gastrocnemius muscles are the only tissue sample 
being analyzed.  
 
RNA isolation, cDNA synthesis, and qualitative real-time qPCR 
Frozen gastrocnemius muscle samples were powdered, and 20 mg of samples were 
suspended in 1 mL of TRIzol reagent and then homogenized using a Polytron for ~5 seconds for 
five times.  These samples were transferred into a 1.5 mL microtube on ice and 200 μL of 
chloroform was added.  After 15 minutes, the samples were vortexed and centrifuged for 25 
minutes.  The supernatant liquid was removed and placed in a new tube where equal amounts of 
70% of Diethyl Pyrocabonate (DEPC) treated ethanol was added as the sample was loaded into a 
RNeasy column.  An RNA isolation kit (K145002; Invitrogen, Carlsbad, CA, USA), was used 
for RNA isolation. 30 uL of DNase treated RNA was collected and the purity of the RNA was 
verified by fluorometry using 260/280 nm ratios read on a Bio-Tek Power Wave XC microplate 
reader (BioTek Instruments Inc., Winooski, VT, USA) with Take3 microvolume plate and Gen5 
software.  Subsequently, using VILO Superscript reagent (11755050; Invitrogen, Carlsbad, CA, 
USA), 1 μg of RNA was reverse-transcribed into cDNA and diluted to 1:100 (10 ng/μL) through 
the process.  Real-time polymerase chain reaction (PCR) was performed on the sample with the 
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use of TaqMan probe reagent, Step-One real-time RT-PCR instrumentation (Applied 
BioSystems, Foster City, CA, USA), and QuantStudio 3 Flex real‐time RT‐PCR instrumentation 
(Applied BioSystems, Foster City, CA). Ct values were analyzed following the manufacturer’s 
protocols of 4 minutes of incubations, 45 cycles of denaturation, and annealing and extension at 
95 °C, 60 °C, and 72°C.  Target TaqMan probes for ACVR2B (Mm00431664) and GRB10 
(Mm01180443) were purchased from Applied Biosystems (Life Technologies).  The final gene 
expressions were calculated using the ΔΔCT method and the relative quantification was 
calculated as 2- ΔΔCT as described previously.48 As a loading control, 18s Ct values did not differ 
between groups within each experiment. 
 
Statistical Analysis 
A One-way ANOVA will be used as the global analysis for each dependent variable.  
Where significant F-ratio is found, statistical differences among means were determined by 
Tukey’s post hoc test.  The comparison-wise error rate, α, is set at 0.05 for all statistical tests.  
All data will be analyzed using the Statistical Analysis System (SAS, version 9.3, Cary, NC, 
USA) and data expression as mean ± Standard error of the mean (SEM). 
 
III. Results 
Induced muscle atrophy by cancer cachexia and hindlimb unloading 
Phenotypic characteristics of mice following induced cancer cachexia and hindlimb 
unloading have been previously reported.45, 46, 49  Following tumor implantation, tissue wet 
weights of the gastrocnemius muscle were ~12% lower in 4-week male tumor-bearing mice 
compared to control mice (p<0.05)45 while female gastrocnemius muscle were ~8% lower in 1-
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week females compared to controls (p<0.05).50  After hindlimb unloading, males and females 
both showed lower body and lower-limb muscle weights (p<0.05).49  Lower overall muscle 
weights in females were significant after 24 hours of unloading while this effect was absent in 
males.49 
 
ACVR2B and GRB10 mRNA Content in Lewis Lung carcinoma male and female mice 
ACVR2B and GRB10 mRNA contents were not significantly different between 
biological sexes for PBS control LLC mice (p>0.05, Figure 1B & 1D).  In LLC induced 
cachexia, female mice had a lower significant mRNA content of ~35% in ACVR2B in the low-
tumor cohort compared to female PBS control mice.  Females were also ~40% and ~30% lower 
at LT and HT compared to 2-week LLC animals, respectively (p<0.05, Figure 2C).  LLC male 
ACVR2B mRNA contents were significantly lower by ~48%, ~56%, and ~36% at one, two, and 
four weeks, respectively, of tumor-bearing compared to PBS control mice (p=0.0006, Figure 
2G).  Despite a significant main effect (p=0.0429), no significant pairwise differences between 
groups were observed in GRB10 mRNA content in tumor-bearing female mice (Figure 2D).  In 
LLC males, GRB10 mRNA content was significantly lower by ~41% after one week of tumor 
implantation compared to LLC PBS control mice (p=0.0094, Figure 2H).  
 
ACVR2B and GRB10 mRNA Content in hindlimb unloading male and female mice 
Cage control mice for hindlimb unloading demonstrated no significant differences 
between biological sexes in either ACVR2B or GRB10 mRNA contents (p>0.05, Figure 1A & 
1C).  ACVR2B mRNA content was not significantly different in hindlimb unloading female 
mice across cohorts (p=0.192, Figure 2A). However, there were significant differences in males 
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with a ~two-fold lower ACVR2B mRNA content at 3 days compared to cage control mice 
(p=0.0233) and 7 days of unloading (p=0.015, Figure 2E).  In females, GRB10 mRNA content 
with hindlimb unloading was not significantly different compared to cage controls (p>0.05, 
Figure 2B) although there were statistical differences observed elsewhere.  HU female mice after 
one day of hindlimb unloading were ~2-fold lower in GRB10 mRNA content compared to 3 
(p=0.0142) and 7 days (p=0.0364) of hindlimb unloading.  GRB10 mRNA content in male mice 
was significantly lower at 2 days and 3 days with ~51% lower content compared to control mice 
while also ~two-fold lower compared to 7 days of hindlimb unloading mice (Figure 2F). 
 
IV. Discussion 
In the present study, I sought to define ACVR2B and GRB10 responses to distinct forms 
of muscle atrophy, cancer cachexia and disuse, in male compared to female mice to identify 
potential roles of these muscle mass-associated proteins across muscle wasting.  The results 
demonstrate ACVR2B and GRB10 are differentially regulated between sexes during the 
development of muscle atrophy induced by cancer cachexia and disuse.  In addition, both 
ACVR2B and GRB10 appear to play a greater role in males during muscle atrophy compared to 
their female counterparts.  Although molecular or phenotypical alterations of skeletal muscle 
have been well reported in muscle atrophy, to my knowledge, no studies have investigated 
molecular mechanisms involved in ACVR2B and GRB10 throughout cancer cachexia and 
disuse-induced wasting, nor while investigating potential sex differences.  Therefore, major 
findings of the current project emphasize the importance of biological sex as well as a necessity 




Male and Female ACVR2B Content Response Differences in HU & LLC Mice 
 The investigation of ACVR2B mRNA content in response to cancer cachexia and disuse-
induced muscle atrophy between sexes, to my knowledge, has rarely been explored.  In this 
project, ACVR2B mRNA content showed significant differences across cohorts of LLC cancer 
cachexia and HU disuse-induced atrophy in a sex-dependent manner.  In fact, although we did 
not find a statistical significance in ACVR2B content in female mice during the development of 
hindlimb unloading-induced muscle atrophy, that of ACVR2B was significantly lower in LLC-
mediated tumor-bearing female mice, indicating ACVR2B may play an important role in 
development of cancer-induced atrophy.  Comparable to these results, a Chopard et al. showed 
no changes in ACVR2B mRNA content in women after two weeks of human immobilization.51  
Although a direct comparison between humans and rodents is limited, current data suggests 
ACVR2B may not be associated with disuse-induced muscle atrophy in females.  
Differing from females, HU male mice showed lower mRNA content in ACVR2B after 2 
and 3 days of unloading with only 3 days being significant.  A previous study examined 
ACVR2B mRNA content in the quadriceps of male participants after 2 weeks of immobilization 
and 6 weeks of rehabilitation.  The ACVR2B content was not influenced by immobilization nor 
by rehabilitation.52  Although there were no ACVR2B content changes observed in immobilized 
humans, the loss seen in HU male mice could be due to the use of different muscles analyzed.  
After 2 weeks of immobilization, the quadriceps muscle had a ~5% decrease in muscle mass 
while the gastrocnemius in mice had a ~12% loss potentially indicating that alterations to 
ACVR2B mRNA content may necessitate a more severe muscle loss.49, 52  
Unlike HU mice, male and female LLC mice both had significantly reduced ACVR2B 
mRNA content.  Female mice had a lower ACVR2B content in the low-tumor cohort (late-stage 
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cancer) compared to PBS control whereas ACVR2B content in males was lower in all tumor-
implanted mice cohorts.  Females have been shown to be more protected from inflammation-
induced muscle wasting and to lose muscle mass more gradually during cancer cachexia which 
may contribute to the differences observed between males and females.6, 18  
LLC male mice displayed significantly low ACVR2B content (~2 folds) during the 
development and progression of cancer cachexia.  Interestingly, lower ACVR2B content was 
observed in early-stage cancer, which remained lower until marked muscle wasting occurs (late-
stage cancer), indicating lower ACVR2B mRNA content may serve as an early biomarker for 
muscle wasting in male cancer cachexia.  Collectively, altered mRNA content of ACVR2B 
seems to play an important role in cancer-mediated muscle wasting to a greater extent in male 
mice. 
There has been much investigation into the therapeutic work of soluble ACVR2B in the 
treatment and prevention of cancer cachexia.7, 53-55  To my knowledge, no studies have 
specifically examined the response of ACVR2B during cancer without the administration of 
soluble ACVR2B or knockout.  Therefore, further studies on the ACVR2B mechanism in a 
cancer-mediated environment are warranted to unravel ambiguous muscle wasting mechanisms 
during the development of cancer cachexia.   
Although ACVR2B has rarely been studied in cancer cachexia, a few interesting findings 
of ACVR2B in response to different forms of muscle atrophy have been reported.  For example, 
a prior study by Yaden et al. investigated the effects of overexpressing activin A and the direct 
consequences on muscle tissue.56  Indeed, overexpression of activin A produced a 52% reduction 
in muscle mass and produced more pronounced decreases than observed with myostatin 
overexpression.56  Differences in muscle mass did not relate to mRNA levels in the current study 
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and further investigation of protein levels may be warranted.  The continuation of ACVR2B’s 
role during muscle atrophy is encouraged to be explored alongside myostatin as differences in 
myostatin activity between males and females could be related to differences in proteins that 
process, bind, and signal transduce myostatin.7 
 
Male and Female GRB10 Content Response Differences in HU & LLC Mice 
Significantly less GRB10 content was observed in male and female hindlimb (HU) mice.  
While both had significant decreases in GRB10 content during HU, females demonstrated lower 
GBR10 content within 24 hours with levels returning to baseline, however, in males this 
reduction was shown after 2 days following HU before returning to baseline.  Similar to this 
pattern, females experiencing disuse have shown significantly lower muscle weights after 1 day 
of unloading, unlike males where lower muscle mass is seen at 2 days of unloading.49  Although 
males and females have similar decreases in cross-sectional area during disuse, research has 
shown females lose muscle faster with males retaining a greater specific strength.6, 20  With 
females experiencing the onset of disuse sooner compared to males while correspondingly 
displaying an earlier decrease of GRB10 mRNA content, the onset of muscle loss is marked by a 
loss in GRB10 mRNA content as also seen in males. 
Male LLC mice displayed an initial loss in GRB10 mRNA content after one week of 
tumor implantation while this effect was not observed in females nor beyond one week in males.  
Changes in muscle mass can significantly affect glucose homeostasis and metabolic health, as 
seen with muscle atrophy, and is associated with decreased insulin sensitivity.15, 58  As females 
have increased insulin receptor gene expression and are more protected against inflammation-
 
20 
induced muscle atrophy, these factors could support the limited differences observed in GRB10 
mRNA content during cancer cachexia in female mice.6, 7 
GRB10 promotes cell proliferation and cell survival.57  Overexpression has been 
observed to result in growth retardation and insulin resistance.57  Looking at short-term muscle 
disuse, skeletal muscle has been shown to be insulin resistant with the response differing across 
subjects.59  The mechanisms regulating disuse-induced insulin resistance between populations 
are not yet known59 but due to GRB10’s influence of binding and modulating the insulin 
receptor, decreases in muscle mass and muscle atrophy could explain decreases in GRB10 
content during cancer cachexia and disuse-induced atrophy.36  Investigation of GRB10 content 
throughout cancer cachexia and disuse-induced wasting is limited as well as knowledge of its 
role in muscle outside of the insulin signaling pathway and further exploration of GRB10’s 
influence in muscle atrophy is encouraged.58   
 
Species Difference of Humans and Mice 
The application of mice modeling for human health studies has been widely and 
extensively used for cancer and disuse studies.60  While mice models have ethical and practical 
advantages, there are fundamental differences between species in regard to human disease 
phenotypes.60, 61  Although limitations exist, cross-species comparisons at the molecular level are 
feasible and insights on the degree of conservation between humans and mice have further 
developed.62 
  There are many biological processes and genetic elements conserved between humans 
and mice.62  Mice models can replicate processes within a disease but may not account for all the 
physiological changes to occur throughout humans.63  Divergences and phenotypic differences 
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between species may result in weakly correlated responses between the two species possibly 
accounting for the differences of the result observed.62  While mice studies are extremely 
beneficial, it is important to consider the species differences that may occur on the molecular and 
transcriptional level when applying to human comparisons.  
 
Vastus Lateralis and Gastrocnemius Fiber Type 
It is essential to consider what particular mouse muscles most similarly represent human 
muscle wasting myopathies as skeletal muscles are dissimilarly affected by varying wasting 
pathologies.61  Human and mouse skeletal muscle profiles vary by muscle type with the soleus 
muscle of the mouse being identified to most closely resemble the molecular expression of 
human skeletal muscle for both control and disease human tissue.60, 61  For this thesis, the 
gastrocnemius was the sole muscle studied.  Had the same muscle been studied for humans and 
mice, results may have been different.  Previous studies have displayed similar atrophic changes 
of the gastrocnemius and vastus lateralis muscle of humans during sarcopenia but comparisons 
for mice have not been reported.64 
 The vastus lateralis is a well-studied muscle in human studies due to its mixed fiber type 
composition and accessibility.65  For both males and females, the vastus lateralis contains 
approximately 42% type I fibers, 35% type IIA fibers, and 23% type IIB fibers.65  Prior research 
has also reported the vastus lateralis encompassing 32% slow-twitch fibers.66  Sex differences 
have been observed for fiber size with males having larger cross-sectional areas compared to 
females by 14%, 28%, and 56% for type I, IIA, and IIB fibers, respectively.65  The 
gastrocnemius muscle of C57BL6J mice are predominantly type II fibers.67  In humans, the 
gastrocnemius has been described as containing 50% slow-twitch fibers.66  Due to the influence 
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of fiber type composition on the wasting characteristics of cancer cachexia and disuse-induced 
wasting in males and females, it is important to take into consideration the difference between 
the vastus lateralis and gastrocnemius muscle.   
While the vastus lateralis and gastrocnemius muscle are both characterized as 
predominantly fast-twitch fibers, the use of different muscle groups could account for the lack of 
basal sexual dimorphic expression observed.  Others who are interested in the potential sexual 
dimorphism of ACVR2B and GRB10 throughout cancer cachexia and disuse-induced wasting 
are encouraged to examine and compare further muscle groups.   
 
V. Conclusion 
 In this study, ACVR2B and GRB10 mRNA content in male and female mice 
experiencing cancer cachexia and disuse-induced muscle atrophy were assessed and ACVR2B 
and GRB10 are dimorphically regulated between sexes during the progression of muscle atrophy 
by induced cancer cachexia and disuse.   Based on my data, ACVR2B content was less during 
cancer cachexia for both male and female mice while having a larger influence and effect in male 
mice. Current data suggests ACVR2B may not be associated with disuse-induced muscle atrophy 
in females but displays a significant decrease in males after 3 days of unloading.  Females are 
also shown to have stable GRB10 mRNA content during cancer cachexia with males displaying 
an initial loss after 1 week with a return to baseline.  Male and female mice both experienced a 
loss in GBR10 mRNA content during disuse with females displaying a faster initial loss than 
compared to males.  This data provides information to help combat cancer cachexia and disuse-
induced muscle atrophy.  With the limited knowledge surrounding ACVR2B and GRB10 content 
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responses throughout cancer cachexia and disuse-induced wasting, further investigation can aid 
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Figure 1. Baseline control comparison of ACVR2B and GRB10 mRNA content between males 
and females.  (A) ACVR2B in HU controls, (B) ACVR2B in LLC controls, (C) GRB10 in HU 
controls, (D) GRB10 in LLC controls.  
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Figure 2. Comparison of mRNA content of ACVR2B and GRB10 during the progression of 
hindlimb unloading (HU) and cancer cachexia (LLC) of the gastrocnemius muscle in male and 
female mice.  (A) ACVR2B in HU females, (B) GRB10 in HU females, (C) ACVR2B in LLC 
females, (D) GRB10 in LLC females, (E) ACVR2B in HU males, (F) GRB10 in HU males (G) 
ACVR2B in LLC males, (H) GRB10 in LLC Male.  Different lettering denotes statistical 
significance between groups, alpha set at p<0.05. 
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In granting its approval, the IACUC has approved only the information provided. Should 
there be any further changes to the protocol during the research, please notify the  IACUC  
in writing (via the Modification form) prior to initiating the changes. If the study period is 
expected to extend beyond                          you must submit a 
prior to that date to avoid any interruption. By policy the IACUC cannot approve a study for 
more than 3 years at a time. 
 
The IACUC appreciates your cooperation in complying with University and Federal 
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To:   Nicholas Greene
Fr:   Craig Coon
Date:   April 12th, 2018
Subject:   IACUC Approval
Expiration Date:   April 5th, 2021
 
 
The Institutional Animal Care and Use Committee (IACUC) has APPROVED your protocol # 18111: Mitochondrial
degeneration in the development of cancer-induced muscle loss in female mice.
  
In granting its approval, the IACUC has approved only the information provided. Should there be any further changes to the
protocol during the research, please notify the IACUC in writing (via the Modification form) prior to initiating the changes. If
the study period is expected to extend beyond April 5th, 2021  you must submit a newly drafted protocol prior to that date to
avoid any interruption.  By policy the IACUC cannot approve a study for more than 3 years at a time. 
  
The following individuals are approved to work on this study:  Nicholas Greene, Tyrone Washington, Megan Rosa, and
Wesley Haynie.   Please submit personnel additions to this protocol via the modification form prior to their start of work.
  
The IACUC appreciates your cooperation in complying with University and Federal guidelines involving animal subjects.
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